Paper Details

  1. Home
  2. Paper Details

A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C.

Author: HigashiY, IshikawaT, KakumuS, TakayanagiM, WakitaT, YoshiokaK

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effectiveness of ribavirin, a broad-spectrum antiviral drug, for treating chronic active hepatitis C. Interferon alfa is a common treatment for hepatitis C, but its benefits are often temporary. This study aimed to determine if ribavirin could be a useful addition to treatment.
Paper Details　
Original Abstract of the Article :
Chronic hepatitis C is a common and often progressive liver disease for which interferon alfa therapy widely spreads, but the beneficial response is frequently transient. Ribavirin is a nucleoside analog with a broad spectrum of antiviral action, and we investigated the efficacy of it in patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0016-5085(93)90727-t

データ提供：米国国立医学図書館（NLM）

A New Hope for Chronic Hepatitis C: Ribavirin and Interferon Beta

Hepatitis C is a persistent liver disease that can be likened to a persistent desert sandstorm, causing damage over time. This study explored a new treatment approach using ribavirin and interferon beta for chronic hepatitis C. Previous treatments, like interferon alfa, were like temporary desert oases, providing relief but not a permanent solution.

Exploring New Treatments for a Persistent Disease

Ribavirin is a nucleoside analog that acts as a potent antiviral agent. It's like a special desert plant that can fight off the harmful invaders. The study aimed to see if this new combo could offer a more sustained and effective response to hepatitis C.

Promising Results

While further research is needed, this pilot study suggests that ribavirin and interferon beta could be a promising new treatment option for chronic hepatitis C. It’s like discovering a new wellspring in the desert, offering hope for a better future.

Dr.Camel's Conclusion

This study serves as a reminder of the importance of continuous research and innovation in battling chronic diseases. It’s like searching for new paths in the vast desert, seeking solutions to improve the lives of those affected.

Date :
  1. Date Completed 1993-08-26
  2. Date Revised 2019-07-07
Further Info :

Pubmed ID

8392957

DOI: Digital Object Identifier

10.1016/0016-5085(93)90727-t

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.